Pages that link to "Q34500215"

The following pages link to Will a global subsidy of new antimalarials delay the emergence of resistance and save lives? (Q34500215):

Displaying 24 items.

• Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum (Q21032477) (← links)
• Subsidising artemisinin-based combination therapy in the private retail sector (Q24186040) (← links)
• Home or community programmes for treating malaria (Q24234694) (← links)
• Dynamic Transmission Economic Evaluation of Infectious Disease Interventions in Low- and Middle-Income Countries: A Systematic Literature Review (Q28072167) (← links)
• Impact of home-based management of malaria on health outcomes in Africa: a systematic review of the evidence (Q28222513) (← links)
• Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania (Q28476037) (← links)
• Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence (Q28538749) (← links)
• Insights into the Affordable Medicines Facility-malaria in Ghana: the role of caregivers and licensed chemical sellers in four regions (Q28833185) (← links)
• Precarity and Preparedness: Non-Adherence as Institutional Work in Diagnosing and Treating Malaria in Uganda (Q30148738) (← links)
• The cost of uncomplicated childhood fevers to Kenyan households: implications for reaching international access targets (Q33267919) (← links)
• Universal access to malaria medicines: innovation in financing and delivery (Q34143045) (← links)
• The Global Challenge of Antimicrobial Resistance: Insights from Economic Analysis (Q34196900) (← links)
• The quest for universal access to effective malaria treatment: how can the AMFm contribute? (Q34221877) (← links)
• Impact of treatment heterogeneity on drug resistance and supply chain costs (Q35221886) (← links)
• Implementation of artemether-lumefantrine treatment policy for malaria at health facilities in Tanzania (Q35727781) (← links)
• Use of over-the-counter malaria medicines in children and adults in three districts in Kenya: implications for private medicine retailer interventions (Q35800877) (← links)
• The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya (Q35842358) (← links)
• Bioeconomic analysis of child-targeted subsidies for artemisinin combination therapies: a cost-effectiveness analysis (Q36111327) (← links)
• Antimalarial drug resistance: a review of the biology and strategies to delay emergence and spread (Q36722524) (← links)
• Towards subsidized malaria rapid diagnostic tests. Lessons learned from programmes to subsidise artemisinin-based combination therapies in the private sector: a review (Q37159612) (← links)
• Treatment-seeking patterns for malaria in pharmacies in five sub-Saharan African countries (Q38603393) (← links)
• Impact of introducing subsidized combination treatment with artemether-lumefantrine on sales of anti-malarial monotherapies: a survey of private sector pharmacies in Huambo, Angola (Q39179328) (← links)
• Will longer antimicrobial patents improve global public health? (Q51103968) (← links)
• Population-level mathematical modeling of antimicrobial resistance: a systematic review (Q64091938) (← links)